Skip to main content

Table 2 Survival analysis of ovarian cancer patients including coexpression of PELP1/ERbeta in the test set (A) and validation set (B)

From: The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer

  Disease-free survival Overall survival
  Univariate 1 Multivariate 2 Univariate 1 Multivariate 2
  P-Value P-Value HR (95%CI) P-Value P-Value HR (95%CI)
Patientsage 0.9 0.09 2.1 (0.9-4.9) 0.9 0.4 1.4 (0.6-3.0)
Histological type (serous vs. non-serous) 0.6 0.6 0.8 (0.4-1.8) 0.4 0.9 0.9 (0.5-2.2)
FIGO stage (I vs. II vs. III vs. IV) <0.001 <0.001 4.4 (1.9-10.1) <0.001 0.007 3.2 (1.4-7.6)
Residual tumor(no vs. yes) <0.001 0.9 0.9 (0.4-2.6) <0.001 0.4 1.6 (0.6-4.3)
ERalpha (negative vs. positive) 0.8 - - 0.9 - -
ERbeta (negative vs. positive) 0.3 - - 0.2 - -
PELP1 (negative vs. positive) 0.004 - - 0.04 - -
PELP1/ERbeta (ERbeta+/PELP1+ vs. others) 0.03 0.004 0.3 (0.1-0.7) 0.02 0.005 0.3 (0.1-0.7)
  Disease-free survival Overall survival
  Univariate 1 Multivariate 2 Univariate 1 Multivariate 2
  P-Value P-Value HR (95%CI) P-Value P-Value HR (95%CI)
Patientsage 0.09 0.4 1.3 (0.7-2.2) 0.005 0.04 2.4 (1.1-5.3)
FIGO stage (I vs. II vs. III vs. IV) 0.001 0.02 1.8 (1.1-3.0) 0.001 0.005 2.5 (1.3-4.7)
Residual tumor (no vs. yes) 0.003 0.1 1.6 (0.9-1.8) 0.02 0.3 1.4 (0.7-2.7)
ERalpha (negative vs. positive) 0.2 - - 0.6 - -
ERbeta (negative vs. positive) 0.7 - - 0.2 - -
PELP1 (negative vs. positive) 0.8 - - 0.9 - -
PELP1/ERbeta (ERbeta+/PELP1+ vs. others) 0.6 0.3 0.7 (0.4-1.3) 0.9 0.3 0.7 (0.3-1.4)
  1. 1Log rank test; 2multivariate Cox-regression analysis, HR=Hazard Ratio, 95%CI= 95% Confidence Interval.